# Sambrinvest

> Sambrinvest is a VC fund in Gosselies backing Biotechnology and Health Care. See 40 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Gosselies, Belgium
- Total investments: 40
- Last investment: Jul 2026
- Lead investor: 10%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company-beta/17940318/
- X (Twitter): https://twitter.com/SambrInvest
- Website: http://www.sambrinvest.be/

Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.

## Contacts

5 contacts available for Sambrinvest. Shizune tracks 1 team members at Sambrinvest. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sambr-invest?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $544k–$24M |
| Series A | $987k–$46M |
| Series B | $4.4M–$45M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 15 | 38% |
| Health Care | 13 | 33% |
| Medical | 7 | 18% |
| Therapeutics | 5 | 13% |
| Pharmaceutical | 5 | 13% |

48 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 15 | 38% |
| Series A | 10 | 25% |
| Series B | 7 | 18% |
| Funding Round | 5 | 13% |
| Pre-Seed | 1 | 3% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 24 | 60% |
| France | 7 | 18% |
| Spain | 1 | 3% |
| The Netherlands | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anne Prignon | Managing Director | 1 | https://shizune.co/investors/profile/anne-prignon |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Brenus Pharma | Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment. | $12.6M | Series A | Jul 20, 2026 |  |
| Vertical Compute | Vertical Compute offers chiplet-based technology that cuts data movement to achieve up to 80% energy savings. | $42.9M | Seed | Mar 04, 2026 |  |
| Enodia Therapeutics | Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases. | $24.2M | Seed | Jan 08, 2026 |  |
| Sunrise | Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $29.2M |  | Sep 25, 2025 |  |
| Elkedonia | Elkedonia is a biotech company dedicated to transforming antidepressant therapy. It aims to develop a groundbreaking antidepressant treatment that is accessible, fast-acting, and free from the risks of dependence, sedation, or psychotic effects. | $12.9M | Seed | Jun 11, 2025 |  |
| ATB Therapeutics | ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients. | $57.2M | Series A | Nov 18, 2024 |  |
| AdipoPharma | AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. |  |  | Nov 11, 2024 |  |
| AdipoPharma | AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. | $10.6M | Series A | Nov 11, 2024 |  |
| AbolerIS Pharma | AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. | $29.2M | Series A | Sep 18, 2023 |  |
| cikisi | Specialized in Web Intelligence (collecting, searching and filtering web information). Help companies and organizations to take advantage of Web information that are relevant to their development. Develops and commercializes Cikisi WMT, a Web Intelligence Solution. | $2.9M | Seed | Sep 01, 2023 |  |

10 of 40 investments shown.

## Co-investors
- [S.R.I.W.](https://shizune.co/investors/profile/s-r-i-w) — VC Fund, 14 deals together
- [Be Angels](https://shizune.co/investors/profile/be-angels) — VC Fund, 5 deals together
- [Investsud](https://shizune.co/investors/profile/investsud) — VC Fund, 5 deals together
- [Meusinvest (Noshaq)](https://shizune.co/investors/profile/meusinvest) — VC Fund, 5 deals together
- [Newton Biocapital](https://shizune.co/investors/profile/newton-biocapital) — VC Fund, 5 deals together
- [SFPI-FPIM](https://shizune.co/investors/profile/sfpi-fpim) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [All Investors in Belgium](https://shizune.co/investors/investors-belgium)
- [All VC Funds in Belgium](https://shizune.co/investors/vc-funds-belgium)
- [SaaS Investors in Belgium](https://shizune.co/investors/saas-investors-belgium)
- [SaaS VC Funds in Belgium](https://shizune.co/investors/saas-vc-funds-belgium)
- [Enterprise VC Funds in Belgium](https://shizune.co/investors/enterprise-vc-funds-belgium)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)

## FAQ

### What does Sambrinvest invest in?

Sambrinvest invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 40 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sambrinvest's check size?

Sambrinvest typically joins rounds of $544k–$24M at Seed, $987k–$46M at Series A and $4.4M–$45M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sambrinvest participates in.

### How do I contact Sambrinvest?

Public channels for Sambrinvest include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sambrinvest?

The team at Sambrinvest includes Anne Prignon (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co